Evercore ISI analysts said the combo vaccine is a key product for Moderna, as it holds the potential ... antibody responses ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

Health officials say eligible residents can receive the COVID-19 vaccine at the same time as or at any time before or after ...

The Moderna laboratories Tuesday reported that their two bivalent Omicron-targeting new messenger RNA (mRNA) technology booster vaccines (mRNA-1273.214 and mRNA-1273.222) have a superior antibody ...

This time around, Moderna and Pfizer’s vaccines target the omicron variant known as KP.2 that was common earlier this year, and Novavax’s new vaccine targets KP.2’s parent strain, JN.1. Keep reading ...

The 2024–2025 COVID-19 vaccines are recommended for everyone aged 6 months and older in the US to target the currently circulating SARS-CoV-2 strains, JN.1 and KP.2.

The updated vaccine covers all major COVID variants that have developed so far, including previous Omicron strains and the new JN1 variant. Thanks to the flexibility of mRNA technology ...

Este artículo estará disponible en español en El Tiempo Latino. Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall ...

Bogoch says the latest vaccine was designed for a sublineage of Omicron called KP.2, which began circulating several months ...

1 Omicron variant is closely related to ... What about Moderna and Novavax's new COVID-19 vaccines? Pfizer and Moderna COVID-19 vaccines are mRNA-based, while Novavax's is protein-based.

A new variant of COVID called XEC — a combination of two Omicron subvariants — is spreading in the middle of flu season.

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers ...